GlassScriptPhysician profile
Lee M Sredzinski
NPI 1356424626
$1,267.49
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $200 · 2021: $15.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $147.41 | 2019-2021 | |
| Glaxosmithkline, LLC. | $123.42 | 2019 | |
| Allergan, INC. | $114.08 | 2019 | |
| Astellas Pharma US INC | $100.45 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $83.79 | 2019-2020 | |
| Lilly USA, LLC | $82.45 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.10 | 2019-2020 | |
| Novo Nordisk INC | $70.56 | 2019 | |
| Pfizer INC. | $69.02 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $50.23 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.13 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $49.93 | 2019-2020 | |
| Amgen INC. | $46.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $39.32 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $31.12 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $23.54 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $23.07 | 2019 | |
| Mylan Specialty L.P. | $22.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.75 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Sredzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.